In Bearbeitung

Bitte warten ...

Einstellungen

Einstellungen

1. US20140010830 - Non-Coding Immunomodulatory DNA Construct

Anmerkung: Text basiert auf automatischer optischer Zeichenerkennung (OCR). Verwenden Sie bitte aus rechtlichen Gründen die PDF-Version.

Claims

1. A DNA construct for immunomodulation comprising at least one sequence motif N 1N 2CGN 3N 4, wherein N is a nucleotide comprising is any A, C, T, or G, and C is deoxycytidine, G is deoxyguanosine, A is deoxyadenosine and T is deoxythymidine, and wherein at least one nucleotide is in L-conformation.
2. The construct according to claim 1, wherein N 1N 2 is selected from the group consisting of GT, GG, GA, AT and AA, and N 3N 4 is selected from the group consisting of CT and TT.
3. The construct according to claim 1, wherein at least one nucleotide in L-conformation is one of the five terminal nucleotides located at the 5′- and/or the 3′-end of a DNA single strand of the DNA construct.
4. The construct according to claim 1, wherein there is at least one G motif of at least three consecutive deoxyguanosines located near the 5′ and/or 3′ end of the DNA construct.
5. The construct according to claim 1, wherein a G motif of at least three consecutive deoxyguanosines is located between two of said sequence motifs N 1N 2CGN 3N 4.
6. The construct according to claim 1, wherein at least five nucleotides are located between two said sequences motifs N 1N 2CGN 3N 4, excluding deoxyguanosine.
7. The construct according to claim 1, wherein the DNA construct is a linear and open-chained comprising single or double-stranded DNA, or is linear, wherein said DNA construct comprises at least one end with a single stranded loop.
8. The construct according to claim 1, wherein the sequence motif N 1N 2CGN 3N 4 is located within a single-stranded and/or a double-stranded region of the DNA sequence.
9. The construct according to claim 1, comprising inter- and/or intramolecular base-pairs and at least one unpaired, single-stranded region.
10. The construct according to claim 21, wherein at least two DNA constructs ligate with each other.
11. The construct according to claim 1, wherein at least one nucleotide in L- or D-conformation is modified with a functional group selected from the group consisting of carboxyl, amine, amide, aldimine, ketal, acetal, ester, ether, disulfide, thiol, and aldehyde.
12. The construct according to claim 11, wherein the modified nucleotide is linked to a compound selected from the group consisting of peptides, proteins, carbohydrates, antibodies, lipids, micelles, vesicles, synthetic molecules, polymers, micro projectiles, metal particles, nanoparticles, and a solid phase.
13. The construct according to claim 1, comprising a first G motif at the 5′ end and three sequence motifs N 1N 2CGN 3N 4, wherein at least five nucleotides are located between the first and second sequence motif N 1N 2CGN 3N 4, excluding deoxyguanosine, and a G motif, which is located between the second and third sequence motif N 1N 2CGN 3N 4, and wherein two of the three 3′ terminal deoxynucleotides are in L-conformation.
14. The construct according to claim 13, comprising at least one further G motif.
15. A pharmaceutical composition comprising a DNA construct according to claim 1.
16. The pharmaceutical composition according to claim 15, comprising additionally a chemotherapeutic.
17. A vaccine comprising a DNA construct according to claim 1.
18. The vaccine according to claim 17, wherein the DNA construct is an adjuvant.
19. A method of treating cancer or an autoimmune disease, comprising administering the DNA construct according to claim 1.
20. A method of modulating the immune system, comprising administering the DNA construct according to claim 1.
21. The DNA construct according to claim 2, wherein a G motif of at least three consecutive deoxyguanosines is located between two of said sequence motif N 1N 2CGN 3N 4.
22. The DNA construct according to claim 2, wherein at least five nucleotides are located between two said sequence motifs N 1N 2CGN 3N 4′ excluding deoxyguanosine.
23. The DNA construction according to claim 2, comprising a first G motif at the 5′ end and three sequence motifs N 1N 2CGN 3N 4, wherein at least five nucleotides are located between the first and second sequence motif N 1N 2CGN 3N 4, excluding deoxyguanosine, and a G motif, which is located between the second and third sequence motif N 1N 2CGN 3N 4, and wherein two of the three 3′ terminal deoxynucleotides are in L-conformation.
24. The DNA construct according to claim 23, comprising at least one further G motif.